These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 7712662)

  • 21. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy?
    Andrassy K; Eschenfelder V
    Thromb Res; 1996; 81(2 Suppl):S29-38. PubMed ID: 8822125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.
    Frydman A
    Haemostasis; 1996; 26 Suppl 2():24-38. PubMed ID: 8707165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of venous thromboembolism: challenging the unfractionated heparin standard.
    Nutescu E; Singh-Khalsa M;
    Pharmacotherapy; 2004 Aug; 24(8 Pt 2):127S-131S. PubMed ID: 15334858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New anticoagulants in ischemic heart disease.
    Verheugt FW
    Presse Med; 2005 Oct; 34(18):1325-9. PubMed ID: 16269997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticoagulants versus antiplatelet agents for acute ischaemic stroke.
    Berge E; Sandercock P
    Cochrane Database Syst Rev; 2002; (4):CD003242. PubMed ID: 12519590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Albers GW; Amarenco P; Easton JD; Sacco RL; Teal P
    Chest; 2004 Sep; 126(3 Suppl):483S-512S. PubMed ID: 15383482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A benefit-risk assessment of agents used in the secondary prevention of stroke.
    MacWalter RS; Shirley CP
    Drug Saf; 2002; 25(13):943-63. PubMed ID: 12381215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations and challenges with existing treatments for thrombosis in cancer patients.
    Schwartz RN
    Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S7-9. PubMed ID: 16286367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
    Dunn CJ; Goa KL
    Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
    Freedman KB; Brookenthal KR; Fitzgerald RH; Williams S; Lonner JH
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):929-38. PubMed ID: 10901307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of the low-molecular-weight heparins.
    Turpie AG
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S329-35. PubMed ID: 9628446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Albers GW; Amarenco P; Easton JD; Sacco RL; Teal P
    Chest; 2008 Jun; 133(6 Suppl):630S-669S. PubMed ID: 18574275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.
    Friedel HA; Balfour JA
    Drugs; 1994 Oct; 48(4):638-60. PubMed ID: 7528134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
    Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
    J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.